IMAC Holdings, Inc. (BACK)
| Market Cap | 2.27K -99.2% |
| Revenue (ttm) | 22.72K -68.5% |
| Net Income | -14.29M |
| EPS | -4.48 |
| Shares Out | 3.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.0006 |
| Previous Close | 0.0006 |
| Day's Range | 0.0006 - 0.0006 |
| 52-Week Range | 0.0002 - 0.2100 |
| Beta | 1.99 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 1, 2026 |
About IMAC Holdings
IMAC Holdings, Inc., through its subsidiary, Ignite Proteomics LLC, provides proteomic product and precision medicine services based on activated protein analysis for the treatment of cancer in the United States. The company offers a reverse phase protein array (RPPA) platform, which can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Holdings, Inc. was founded in 2000 and is based in Franklin, Tennessee. [Read more]
Financial Performance
Financial StatementsNews
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study
IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery
Project will leverage Ignite Proteomics' reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Pro...
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein ...
Ignite Proteomics complete acquisition of PLA code 0249U
Ignite Proteomics, a subsidiary of IMAC Holdings (BACK), announced the completed transfer of Proprietary Laboratory Analyses, or PLA, code 0249U – originally issued to Theralink Technologies- to Ignit...
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA)...
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC H...
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
Nashville, TN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”) has launched Ignite Proteomics LLC (“Ignite”), its new subsidiary dedicated to he...
IMAC Holdings receives Nasdaq notification of deficiency
IMAC Holdings (BACK) announced that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC on November 22, 2024. The Notice indicat...
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
FRANKLIN, TN, Nov. 22, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it received an expected deficiency notification letter from the Listin...
IMAC Holdings granted extension by Nasdaq to regain compliance
IMAC announced that it has received an exception from the Listing Qualifications Staff of The Nasdaq Stock Market to regain compliance with Nasdaq Listing Rule 5250(c)(1). This exception extends the…
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
FRANKLIN, TN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (“IMAC” or the “Company”) (NASDAQ: BACK) today announced that it has received an exception from the Listing Qualifications Staff of ...
IMAC Holdings launches Ignite Proteomics subsidiary
IMAC Holdings announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array technology through its newly establ...
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an...
IMAC Holdings receives noncompliance notification from Nasdaq
IMAC Holdings announced that it received an expected deficiency notification letter from Nasdaq on August 21. The notice indicated that the company was not in compliance with Nasdaq Listing Rule…
IMAC Holdings appoints Matthew Schwartz, Peter Beitsch to board
IMAC Holdings announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. Schwartz currently serves as a practicing Radiation Oncologist...
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ: BACK) (the “Company” or “IMAC”), a leading innovator in proteomics research and technology, announced the appointment of Dr. ...
IMAC Holdings files to sell common stock, warrants, no amount given
16:51 EDT IMAC Holdings files to sell common stock, warrants, no amount given
IMAC Holdings appoints Faith Zaslavsky as CEO
IMAC Holdings (IMAC) announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed CEO, succeeding Jeff Ervin, to lead newly acquired assets in the…
IMAC Holdings Announces Leadership Succession
Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today announced leadership transitions to the board...
IMAC Holdings acquires assets of Theralink
On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings and Theralink Technologies, BACK acquired the assets of Theralink, othe...
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK) ...
IMAC Holdings Inc trading halted, volatility trading pause
09:32 EDT IMAC Holdings Inc trading halted, volatility trading pause
IMAC Holdings price target lowered to $10 from $34.50 at Ascendiant
Ascendiant analyst Edward Woo lowered the firm’s price target on IMAC Holdings to $10 from $34.50 and keeps a Buy rating on the shares. The company’s Q3 reported was “about…
IMAC Holdings regains compliance with Nasdaq minimum bid price rule
IMAC Holdings announced that it has received notice from The Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing…